Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of guselkumab on cardiovascular risk markers in moderate to severe plaque psoriasis
2020-004061-39Phase 4Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of guselkumab in plaque psoriasis, sponsored by Janssen Pharmaceutical. Primary endpoint: Change from baseline in CFR. Started May 2021; status: terminated.
02
Drugs
guselkumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2020-004061-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004061-39.